<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01525459</url>
  </required_header>
  <id_info>
    <org_study_id>MNC-Glioma-1-4</org_study_id>
    <nct_id>NCT01525459</nct_id>
  </id_info>
  <brief_title>Gene Expression, Immunological Status and Metabolome in Glioma Patients</brief_title>
  <official_title>Monitoring and Analysis of Gene Expression, Immunological Status and Metabolome in Peripheral Blood Mononuclear Cells and Their Specific Subpopulations (CD4+ T Cells and CD56+ NK Cells) in Surgically Treated Glioma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Biology, Slovenia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blood Transfusion Centre of Slovenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Biology, Slovenia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study on glioma patients treated with brain surgery is focusing on the analysis of their
      transcriptome expression profile measured in two immune cell populations, CD4+ T cells and
      CD56+ NK cells. The results of analysis will be compared to the reference data of healthy
      population. Furthermore, the metabolomic and immunological status will also be monitored and
      compared to healthy group reference data, before and after the surgery*. With comparative
      crossomics analysis the investigators intend to possibly identify new diagnostic and
      prognostic biological markers for the relapse of the disease. The results are expected to
      convey a deeper insight into pathophysiology of the glioma as well as into the mechanisms of
      the current surgical therapy.

      * The healthy reference data have been published in collaborative efforts of BTC, UMC and NIB
      (Gruden et al. 2012).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Transcriptome profile of CD4+ T and CD56+ NK cells</measure>
    <time_frame>within 10 days before surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Transcriptome profile of CD4+ T and CD56+ NK cells</measure>
    <time_frame>one day after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Transcriptome profile of CD4+ T and CD56+ NK cells</measure>
    <time_frame>within 10 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolite profiling in blood plasma samples</measure>
    <time_frame>within 10 days before surgery, one day after surgery and once more within 10 days after surgery surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte subpopulation assessment in peripheral blood samples</measure>
    <time_frame>within 10 days before surgery, one day after surgery and once more within 10 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody profiling in blood plasma samples</measure>
    <time_frame>within 10 days before surgery, one day after surgery and once more within 10 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miRNA profiling in blood plasma samples</measure>
    <time_frame>within 10 days before surgery, one day after surgery and once more within 10 days after surgery surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteomic analysis of blood plasma samples</measure>
    <time_frame>within 10 days before surgery, one day after surgery and once more within 10 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Glioma patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Glioma resection</intervention_name>
    <description>Patients will be treated with the standard surgical therapy - glioma resection.</description>
    <arm_group_label>Glioma patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.</description>
    <arm_group_label>Glioma patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, blood plasma, peripheral blood mononuclear cells, CD4+ T cells, CD56+ NK cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Glioma patients treated with surgical resection of the tumor
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  malignant glioma = glioblastoma (WHO IV) patients

        Exclusion Criteria:

          -  pregnancy

          -  metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamara Lah Turnšek, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Biology, Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristina Gruden, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Biology, Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tamara Lah Turnšek, PhD</last_name>
    <phone>+386-59-23-27-03</phone>
    <email>tamara.lah@nib.si</email>
  </overall_contact>
  <location>
    <facility>
      <name>Blood Transfusion Centre of Slovenia</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primož Rožman, MD, PhD</last_name>
      <phone>+386-1-5438-100</phone>
      <email>primoz.rozman@ztm.si</email>
    </contact>
    <contact_backup>
      <last_name>Matija Veber, dipl. biotech.</last_name>
      <phone>+386-51-649-350</phone>
      <email>matija.veber@ztm.si</email>
    </contact_backup>
    <investigator>
      <last_name>Primož Rožman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, University Medical Centre Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjan Koršič, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Marjan Koršič, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute of Biology</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Lah Turnšek, PhD</last_name>
      <phone>+386-59-23-27-03</phone>
      <email>tamara.lah@nib.si</email>
    </contact>
    <investigator>
      <last_name>Kristina Gruden, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <link>
    <url>http://www.nib.si</url>
    <description>Official internet page of the Slovenian National Institute of Biology</description>
  </link>
  <link>
    <url>http://systher.biologie.hu-berlin.de</url>
    <description>Official internet page of the project SYSTHER (Systems Biology Tools Development For Cell Therapy And Drug Development)</description>
  </link>
  <reference>
    <citation>Gruden K, Hren M, Herman A, Blejec A, Albrecht T, Selbig J, Bauer C, Schuchardt J, Or-Guil M, Zupančič K, Svajger U, Stabuc B, Ihan A, Kopitar AN, Ravnikar M, Knežević M, Rožman P, Jeras M. A &quot;crossomics&quot; study analysing variability of different components in peripheral blood of healthy caucasoid individuals. PLoS One. 2012;7(1):e28761. doi: 10.1371/journal.pone.0028761. Epub 2012 Jan 12.</citation>
    <PMID>22253695</PMID>
  </reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2012</study_first_submitted>
  <study_first_submitted_qc>January 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2012</study_first_posted>
  <last_update_submitted>February 6, 2012</last_update_submitted>
  <last_update_submitted_qc>February 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Biology, Slovenia</investigator_affiliation>
    <investigator_full_name>Tamara Lah Turnsek</investigator_full_name>
    <investigator_title>Director of the National Institute of Biology, Slovenia</investigator_title>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>PBMC subpopulations</keyword>
  <keyword>Gene expression</keyword>
  <keyword>Metabolomics</keyword>
  <keyword>Immunological status</keyword>
  <keyword>miRNA</keyword>
  <keyword>Proteomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

